Effect of ticagrelor on acute kidney injury in septic rats and its underlying mechanism

Cheng Yu1, Cui-Min Gao1, Na Xie1

  • 1Department of Anesthesiology, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.

Insights

Ticagrelor treatment effectively reduced kidney damage and inflammation in a rat model of sepsis-induced acute kidney injury (AKI). These protective effects are linked to the downregulation of the CD62P pathway, suggesting a novel therapeutic mechanism.

Area of Science:

  • Nephrology
  • Pharmacology
  • Immunology

Background:

  • Sepsis-induced acute kidney injury (AKI) is a critical complication with high mortality.
  • The CD62P pathway plays a significant role in inflammatory responses and tissue damage during sepsis.
  • Ticagrelor, an antiplatelet drug, has shown potential in various inflammatory conditions.

Purpose of the Study:

  • To investigate the therapeutic effects of ticagrelor on sepsis-induced AKI in a rat model.
  • To elucidate the underlying mechanisms, specifically the involvement of the CD62P pathway.

Main Methods:

  • A rat model of sepsis-induced AKI was established using cecal ligation and puncture (CLP).
  • Rats were treated with different doses of ticagrelor (clinical and loading doses) or distilled water.
  • Key markers including serum creatinine, CD62P, interleukin-1β, myeloperoxidase activity, and renal cell apoptosis were assessed.

Main Results:

  • CLP significantly increased serum creatinine, CD62P, IL-1β, myeloperoxidase activity, and renal cell apoptosis compared to normal and sham groups.
  • Ticagrelor treatment significantly reduced these elevated markers in a dose-dependent manner.
  • CD62P expression was found to be closely associated with the development of sepsis-induced AKI.

Conclusions:

  • Ticagrelor demonstrates significant renoprotective effects in a rat model of sepsis-induced AKI.
  • The mechanism of action involves the reduction of inflammation, neutrophil infiltration, and renal cell apoptosis.
  • Downregulation of the CD62P pathway is a key mechanism underlying ticagrelor's therapeutic benefits in sepsis-induced AKI.

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
127
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
508
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
252
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
401
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
113
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
178